Molecular analysis of CCR-3 events in eosinophilic cells.
CCR-3 is a major receptor involved in regulating eosinophil trafficking. Initial analysis of chemokine receptors has demonstrated unique receptor events in different cell types, indicating the importance of investigating CCR-3 events in eosinophilic cell lines. We now report that the eosinophilic cell line, acute myelogenous leukemia (AML) 14.3D10, expresses eosinophil granule proteins and eotaxin, but has no detectable expression of eosinophil chemokine receptors. Treatment of the cell line with butyric acid and IL-5 results in a dose-dependent synergistic induction of CCR-3 and, to a lesser extent, CCR-1 and CCR-5. Interestingly, using a luciferase reporter construct under the control of the hCCR-3 promoter, the uninduced and induced cells display high, but comparable, levels of promoter activity. Differentiated AML cells developed enhanced functional activation, as indicated by adhesion to respiratory epithelial cells and chemokine-induced transepithelial migration. Chemokine signaling did not inhibit adenylate cyclase activity even though calcium transients were blocked by pertussis toxin. Additionally, chemokine-induced calcium transients were inhibited by pretreatment with PMA, but not forskolin. Eotaxin treatment of differentiated AML cells resulted in marked down-modulation of CCR-3 expression for at least 18 h. Receptor internalization was not dependent upon chronic ligand exposure and was not accompanied by receptor degradation. Thus, CCR-3 is a late differentiation marker on AML cells and uses a signal transduction pathway involving rapid and prolonged receptor internalization, calcium transients inhibitable by protein kinase C but not protein kinase A, and the paradoxical lack of inhibition of adenylate cyclase activity.
Zimmermann
N
N
Division of Pulmonary Medicine, Department of Pediatrics, Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
Daugherty
B L
BL
Stark
J M
JM
Rothenberg
M E
ME
D037361:Adenylate Cyclase Toxin; D000067956:Adenylyl Cyclase Inhibitors; D020148:Butyric Acid / Q000494:pharmacology; D020013:Calcium Signaling / Q000276:immunology; D002454:Cell Differentiation / Q000276:immunology; D002465:Cell Movement / Q000276:immunology; D002999:Clone Cells; D015536:Down-Regulation / Q000276:immunology; D004789:Enzyme Activation / Q000276:immunology; D004804:Eosinophils / Q000276:immunology* / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D015848:Interleukin-5 / Q000502:physiology; D015470:Leukemia, Myeloid, Acute / Q000201:enzymology / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D008024:Ligands; D037342:Pertussis Toxin; D011401:Promoter Regions, Genetic / Q000187:drug effects / Q000276:immunology; D011493:Protein Kinase C / Q000378:metabolism; D054397:Receptors, CCR3; D019707:Receptors, Chemokine / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D015533:Transcriptional Activation / Q000187:drug effects / Q000276:immunology; D014407:Tumor Cells, Cultured; D010566:Virulence Factors, Bordetella / Q000494:pharmacology
D037361:Adenylate Cyclase Toxin; D000067956:Adenylyl Cyclase Inhibitors; C515350:CCR3 protein, human; D015848:Interleukin-5; D008024:Ligands; D054397:Receptors, CCR3; D019707:Receptors, Chemokine; D010566:Virulence Factors, Bordetella; D020148:Butyric Acid; D037342:Pertussis Toxin; D011493:Protein Kinase C